Results 181 to 190 of about 118,116 (256)

Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosis. [PDF]

Blood Adv
Lopedote P, Evans B, Marchetti A, Chen T, Moscvin M, Boullt S, Bolli N, Bianchi G.   +7 more
europepmc   +1 more source

Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis [PDF]

, 2017
Tamer Rezk, Carol Whelan, Helen J. Lachmann, Marianna Fontana, Sajitha Sachchithanantham, Shameem Mahmood, Fakhar Z. Khan, Raj Khiani, Joseph Tomson, Taryn Youngstein, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar   +12 more
openalex   +1 more source

Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases

Advanced Science, EarlyView.
Genetic fusion of a CD38 enzymatic domain to antibody scaffolds allows site‐specific conjugation of small‐molecule ligands. Using this approach, a PSMA ligand DUPA is conjugated with an anti‐human CD3 Fab antibody. The resulting bispecific anti‐CD3‐DUPA conjugate facilitates recruitment and activation of cytotoxic T cells against PSMA‐expressing ...
Sunny H. Kim, Arshad J. Ansari, Lei Zhang, Guoyun Kao, Thuc Oanh Hoang, Zeyu Zhang, Srinivasarao Singireddi, Benjamin B. Katz, Yong Zhang   +8 more
wiley   +1 more source

The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. [PDF]

Blood Adv
Ramachandran R, Shah D, Luo C, Shah V, Cliff ERS, Sanchorawala V, Lentzsch S, Chakraborty R.   +7 more
europepmc   +1 more source

A Programmable Nanoreactor Orchestrates Cascade of DNA Sensing to Amplify cGAS‐STING Activation for Cancer Immunotherapy

Advanced Science, EarlyView.
A programmable nanoreactor was engineered for precise cGAS‐STING pathway activation in cancer immunotherapy. This strategy bridges targeted tumor DNA damage with DC immunomodulation, providing a translatable platform to unlock innate and adaptive antitumor immunity.
Shuang Liang, Yiwei Tian, Feiyu Zhao, Yue Han, Kongshuo Ma, Linna Hai, Kaiqing Yun, Yueyang Zhao, Siqi Zhang, Ziyi Zhang, Yuxuan Peng, Kuan Hu, Jing Zhong, Bai Xiang, Zhaohui Wang   +14 more
wiley   +1 more source

Intraoral hemorrhagic bullae as the first sign of immunoglobulin light chain amyloidosis. [PDF]

CMAJ
Dominguez-Lopez RM, Naharro-Rodriguez J.
europepmc   +1 more source

The biology of immunoglobulin free light chains in kidney disease: a study of Monoclonal and Polyclonal light chains [PDF]

, 2012
Kolitha Basnayake
openalex  

Serum levels of immunoglobulin free light chains in patients with chronic hepatitis C presenting cryoglobulinemia

, 2014
Isabela S. Oliveira, Milena Santana Cabral, Larissa Santana de Jesus, Raymundo Paraná, Ajax Mercês Atta, Maria Atta   +5 more
openalex   +1 more source

An immunoglobulin light chain from a lupus-prone mouse induces autoantibodies in normal mice. [PDF]

, 1990
Antonio Puccetti, Tamio Koizumi, Paola Migliorini, J André-Schwartz, K J Barrett, Robert S. Schwartz   +5 more
openalex   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source